A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries — AD-impaCT

Dermatitis Atopic Clinical Trial

Official title:
A Real-World Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Patients Receiving Dupilumab Therapy, With Atopic Dermatitis Control Tool in Gulf Countries

Status Active, not recruiting

Clinical Trial Summary

Primary objective: To assess the disease control of moderate to severe atopic dermatitis in patients aged 12 years and above treated with dupilumab therapy using Atopic Dermatitis Control Tool (ADCT) after 24 weeks of treatment. Secondary objectives: - To figure the proportion of patients with reduction of ADCT score by 5 points after 4, 12, and 24 weeks of treatment. - To figure the proportion of patients with ADCT score less than 7 at weeks 4, 12, and 24. - Assess the effectiveness of dupilumab in moderate to severe atopic dermatitis (AD) patients, using the severity score as routine practice SCORing Atopic Dermatitis (SCORAD). - To describe comorbidities related to type 2 inflammation. - To characterize the safety profile of dupilumab in the local Gulf population. - To evaluate treatment satisfaction in the local Gulf population.

Clinical Trial Description

24 weeks ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05214326
Study type	Observational
Source	Sanofi
Contact
Status	Active, not recruiting
Phase
Start date	January 18, 2022
Completion date	May 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04135560` - A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants	Phase 1
Active, not recruiting	`NCT03992417` - Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Completed	`NCT04718870` - Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis	Phase 4
Completed	`NCT05235724` - A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
Recruiting	`NCT05492578` - Long-Term Safety and Efficacy Evaluation of Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis	Phase 2
Active, not recruiting	`NCT03687359` - Observational Evaluation of Atopic Dermatitis in Pediatric Patients
Completed	`NCT04823130` - Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis	Phase 4
Active, not recruiting	`NCT03849716` - Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)